Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles

Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles

Effective systemic treatment for hepatocellular carcinoma (HCC) remains urgently needed. Sorafenib is the first FDA-approved systemic treatment for HCC. However, individual HCC patents’ response to sorafenib varies greatly. How to enhance the anti-HCC effect of sorafenib is still a significant chall...

Full description

Bibliographic Details
Main Authors: Chenghua Song, Jia Zhang, Ruichao Wen, Qingshan Li, Jiaxuan Zhou, Xiaoli liu, Zheng Wu, Yi Lv, Rongqian Wu
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Materials Today Bio
Subjects:
Hepatocellular carcinoma
Tim-3 siRNA
Sorafenib
pH-triggered nanoparticle
Co-delivery
Online Access:http://www.sciencedirect.com/science/article/pii/S259000642200148X

Similar Items

Similar Items